ViiV makes EU and North American filings for HIV treatment
This article was originally published in Scrip
Executive Summary
ViiV Healthcare has submitted regulatory applications in the US, EU and Canada for its investigational integrase inhibitor, dolutegravir (S/GSK1349572), for the treatment of HIV infection in adults and adolescents (aged 12 years and older).